JP4426929B2 - 脳卒中・無症候性脳梗塞のスクリーニング方法 - Google Patents
脳卒中・無症候性脳梗塞のスクリーニング方法 Download PDFInfo
- Publication number
- JP4426929B2 JP4426929B2 JP2004255976A JP2004255976A JP4426929B2 JP 4426929 B2 JP4426929 B2 JP 4426929B2 JP 2004255976 A JP2004255976 A JP 2004255976A JP 2004255976 A JP2004255976 A JP 2004255976A JP 4426929 B2 JP4426929 B2 JP 4426929B2
- Authority
- JP
- Japan
- Prior art keywords
- polyamine
- acrolein
- plasma
- cerebral infarction
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010008118 cerebral infarction Diseases 0.000 title claims description 38
- 208000006011 Stroke Diseases 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 20
- 238000012216 screening Methods 0.000 title claims description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 96
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 5
- PEIAVFKXKCRVCG-NSHDSACASA-N (2s)-6-amino-2-[formyl(piperidin-1-yl)amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)N(C=O)N1CCCCC1 PEIAVFKXKCRVCG-NSHDSACASA-N 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims 1
- 102100037209 Peroxisomal N(1)-acetyl-spermine/spermidine oxidase Human genes 0.000 description 52
- 108010089000 polyamine oxidase Proteins 0.000 description 52
- 229920000768 polyamine Polymers 0.000 description 41
- 230000000694 effects Effects 0.000 description 34
- 208000026106 cerebrovascular disease Diseases 0.000 description 23
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 20
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 20
- 239000004472 Lysine Substances 0.000 description 13
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 12
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 10
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 229940063675 spermine Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 229940063673 spermidine Drugs 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000014644 Brain disease Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000005700 Putrescine Substances 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000007833 oxidative deamination reaction Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZAXCZCOUDLENMH-UHFFFAOYSA-N 3,3,3-tetramine Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UODZHRGDSPLRMD-UHFFFAOYSA-N sym-homospermidine Chemical compound NCCCCNCCCCN UODZHRGDSPLRMD-UHFFFAOYSA-N 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- QZBYOYPROVGOGE-UHFFFAOYSA-N aminopropylcadaverine Chemical compound NCCCCCNCCCN QZBYOYPROVGOGE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- DODDBCGMRAFLEB-UHFFFAOYSA-N thermospermine Chemical compound NCCCCNCCCNCCCN DODDBCGMRAFLEB-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Description
脳疾患患者における血漿アクロレイン含有量を検討した。健常人、脳梗塞・脳内出血群、その他脳疾患群の3群に分けて、採取した血液のアクロレイン含有量を比較した。
実施例1で用いた患者血漿中のポリアミンオキシダーゼ活性を測定した。その結果を図2に示す。血漿中のポリアミンオキシダーゼの活性は、10mM-Tris塩酸塩(pH7.5)、0.2mMの基質(スペルミン、スペルミジン及びプトレスシン)及び0.03mlの患者血清の反応混合液0.15mlを37℃にて48時間インキュベーションすることにより測定した。0.02mlの反応混合液に最終濃度5%のトリクロロ酢酸(TCA)を加え、遠心分離した。得られた上清の一部をポリアミンのアッセイに使用した。アミンオキシダーゼ活性は患者血清1ml当たりの、スペルミン分解により生成したスペルミジン量(nmol/ml plasma/48h)で表示した。
被験者の許可・同意を得て、MRIにより頭部の断面画像解析を行い、脳梗塞の有無を調べた。健常者(図3A)、脳梗塞患者(図3B)、および病名の診断はついていないが血漿中のアクロレイン量とポリアミンオキシダーゼ活性が極めて高い値を示した被験者(図3C)におけるMRI断層写真を示す。図3Cに示されるように、血漿中のアクロレイン量とポリアミンオキシダーゼ活性が高かった患者では、両側前頭・側頭頂および基底核に多発性の梗塞が認められた。また脳の萎縮および動脈硬化も認められた。
性およびアクロレイン含有量の変化についての比較検討
急性期脳梗塞患者1名について、発症当日(1日)、2日目および一週間後(7日)における頭部断面画像(MRI, CT)の変化と、それに伴う血漿ポリアミンオキシダーゼ活性およびアクロレイン含有量の変化を調べた。頭部断面画像の写真を図4に示す。発症当日では、T2強調MRIおよびCTに明瞭な梗塞像は見られなかった。一方発症当日の血漿ポリアミンオキシダーゼ活性とFDP-Lys量は、それぞれ6.6nmol SPD増加/ml血漿と18.4nmol/ml血漿であった。この結果から、血漿ポリアミンオキシダーゼ活性は健常者群の2倍程度であり、有意に高値であることが確認された。発症2日目の頭部断面画像(MRI)と一週間後の頭部断面画像(CT)では、左側頭葉に明瞭な梗塞像が認められた。発症一週間後の血漿ポリアミンオキシダーゼ活性とFDP-Lys量は、それぞれ7.2nmol SPD増加/ml血漿と23.0nmol/ml血漿であった。よって血漿ポリアミンオキシダーゼ活性の上昇と共に、血漿アクロレイン含有量の有意な増加も認められた。以上に示されるように、急性期梗塞患者においては血漿ポリアミンオキシダーゼ活性の上昇が、MRIもしくはCTにおける梗塞像の出現に先立って起こることが確認された。
Claims (3)
- 脳卒中・無症候性脳梗塞の患者をスクリーニングする方法であって、被験者から採取されたサンプルにおける血しょう中のアクロレインの含量が健常者と比較して高いことを指標とする工程を具え、前記アクロレインの含量はアクロレイン付加アミノ酸に対する抗体を用いて測定される、方法。
- 前記アクロレインの含量は酵素免疫測定法(ELISA)により測定される、請求項1記載の方法。
- 前記アクロレイン付加アミノ酸が、N−ホルミルピペリジノ・リジン(FDP−Lys)である、請求項1または2記載の方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004255976A JP4426929B2 (ja) | 2004-03-25 | 2004-09-02 | 脳卒中・無症候性脳梗塞のスクリーニング方法 |
PCT/JP2005/006429 WO2005093412A1 (ja) | 2004-03-25 | 2005-03-25 | ポリアミン、アクロレインの含有量又はポリアミンオキシダーゼ活性又はその蛋白質量を指標とした脳卒中・無症候性脳梗塞の診断方法 |
EP05727387.2A EP1729129B1 (en) | 2004-03-25 | 2005-03-25 | Method of diagnosing apoplectic stroke/asymptomatic brain infarction using polyamine and acrolein contents, polyamine oxidase activity or protein content thereof as indication |
CA002561286A CA2561286A1 (en) | 2004-03-25 | 2005-03-25 | A diagnostic method for stroke/asymptomatic cerebal infarction using polyamine or acrolein content, polyamine oxidase activity or protein content thereof as an indicator |
US10/599,221 US8715921B2 (en) | 2004-03-25 | 2005-03-25 | Method of diagnosing apoplectic stroke/asymptomatic brain infarction using acrolein content |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004089063 | 2004-03-25 | ||
JP2004255976A JP4426929B2 (ja) | 2004-03-25 | 2004-09-02 | 脳卒中・無症候性脳梗塞のスクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005304476A JP2005304476A (ja) | 2005-11-04 |
JP4426929B2 true JP4426929B2 (ja) | 2010-03-03 |
Family
ID=35056303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004255976A Active JP4426929B2 (ja) | 2004-03-25 | 2004-09-02 | 脳卒中・無症候性脳梗塞のスクリーニング方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8715921B2 (ja) |
EP (1) | EP1729129B1 (ja) |
JP (1) | JP4426929B2 (ja) |
CA (1) | CA2561286A1 (ja) |
WO (1) | WO2005093412A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687231B2 (en) * | 2006-01-30 | 2010-03-30 | Yamasa Corporation | Method for determining degree of negative effect of macrophages on vertebrate |
JP5339227B2 (ja) * | 2007-05-18 | 2013-11-13 | 国立大学法人 千葉大学 | アクロレイン、インターロイキン−6及びcrpの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法 |
KR101550253B1 (ko) * | 2007-10-22 | 2015-09-04 | 알프레사 파마 가부시키가이샤 | 면역학적 미소 입자의 응집 반응을 사용하는 검체의 아크롤레인 부가체의 측정 방법 및 측정용 키트 |
WO2012007531A2 (en) | 2010-07-13 | 2012-01-19 | Frank Madeo | Methods and compositions for diagnosing medical conditions |
US20140208835A1 (en) * | 2011-06-14 | 2014-07-31 | Amine Pharma Research Institute Co., Ltd. | Method for determination of stroke and/or cerebral infarction using 3-hpma as measure |
ES2415579B1 (es) | 2011-09-28 | 2014-11-17 | Instituto Tecnológico De Castilla Y León | Procedimiento y dispositivo electrónico multiagente con control difuso para la detección del ictus cerebral lateral. |
WO2015163342A1 (ja) * | 2014-04-23 | 2015-10-29 | 塩野義製薬株式会社 | 脳卒中診断マーカー |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733933A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US6391899B1 (en) | 1998-07-17 | 2002-05-21 | North Shore—Long Island Jewish Research Institute | Compounds and compositions for treating tissue ischemia |
JP2002541162A (ja) * | 1999-04-13 | 2002-12-03 | ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート | 発作による脳障害防止法 |
JP2002181820A (ja) * | 2000-12-14 | 2002-06-26 | Ikagaku:Kk | 動脈硬化性病変の診断用キット |
JP2002281999A (ja) | 2001-03-29 | 2002-10-02 | Kazue Igarashi | 尿毒症治療用化合物、その選別方法および該化合物を含有する尿毒症治療剤 |
-
2004
- 2004-09-02 JP JP2004255976A patent/JP4426929B2/ja active Active
-
2005
- 2005-03-25 EP EP05727387.2A patent/EP1729129B1/en not_active Not-in-force
- 2005-03-25 WO PCT/JP2005/006429 patent/WO2005093412A1/ja active Application Filing
- 2005-03-25 CA CA002561286A patent/CA2561286A1/en not_active Abandoned
- 2005-03-25 US US10/599,221 patent/US8715921B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8715921B2 (en) | 2014-05-06 |
EP1729129A1 (en) | 2006-12-06 |
JP2005304476A (ja) | 2005-11-04 |
EP1729129B1 (en) | 2013-05-29 |
WO2005093412A1 (ja) | 2005-10-06 |
CA2561286A1 (en) | 2005-10-06 |
US20080254495A1 (en) | 2008-10-16 |
EP1729129A4 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2146209B1 (en) | Neurodegenerative markers for Alzheimer's disease | |
JP5241710B2 (ja) | 神経変性障害の診断および早期診断のためのinvitroマルチパラメータ測定法 | |
Schröder et al. | Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging | |
Galasko | Biomarkers for Alzheimer's disease–clinical needs and application | |
Kiđemet‐Piskač et al. | Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia | |
US8715921B2 (en) | Method of diagnosing apoplectic stroke/asymptomatic brain infarction using acrolein content | |
CA2571692A1 (en) | Biomarkers of alzheimer's disease | |
Masania et al. | Urinary metabolomic markers of protein glycation, oxidation, and nitration in early-stage decline in metabolic, vascular, and renal health | |
JPWO2015060317A1 (ja) | 神経変性疾患の検査方法 | |
Tsolaki et al. | Correlation of rCBF (SPECT), CSF tau, and congnitive function in patients with dementia of the Alzheimer's type, other types of dementia, and congrol subjects | |
JP5339227B2 (ja) | アクロレイン、インターロイキン−6及びcrpの含有量、ポリアミンオキシダーゼ活性又はポリアミンオキシダーゼの蛋白質量、並びに、被験者の年齢を指標とした脳卒中・無症候性脳梗塞の検出方法 | |
JP6478268B2 (ja) | 尿中のアクロレイン代謝物及びクレアチニンを指標とする認知機能障害の検査方法 | |
WO2020228132A1 (zh) | 脑出血外周血标志物及其应用 | |
WO2006070740A1 (ja) | アルツハイマー病の検査方法 | |
JP6074685B2 (ja) | 3−hpmaを指標とした脳卒中及び/又は脳梗塞の判定方法 | |
JP7461037B2 (ja) | 睡眠障害を判定するためのバイオマーカー | |
Laman et al. | Body fluid markers to monitor multiple sclerosis: the assays and the challenges | |
US20230280357A1 (en) | Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies | |
JP4687647B2 (ja) | 血糖制御状態の検査方法 | |
Şambel et al. | Serum Mindin, Nephrin and Podocalyxin Levels in Patients with Type 1 Diabetes: Are These New Markers to Detect the Development of Nephropathy? | |
Ge et al. | Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of α-Synuclein Autoantibodies in Human Plasma | |
US20210255201A1 (en) | Blood-based methods for determing a-beta amyloidosis | |
Crespi et al. | INFLAMMASOME PROTEINS AS BIOMARKERS OF TRAUMATIC BRAIN INJURY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060622 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070830 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071015 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081031 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090914 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091211 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4426929 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |